JAK Inhibitors for Vitiligo: More Skin Response Over Time medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Almirall S.A.: Almirall's Nine-month 2023 Results: finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Almirall achieves Net Sales growth of 6.4%, driven by strong European dermatology performanceAlmirall's European Dermatology business continued to be the driving force behind Almirall's strong performance in the first nine months of 2023, with a growth rate of 15.9% underpinned by the success of Ilumetri® and other.
The data presents compelling evidence for the sustained efficacy and safety of the oral JAK1 inhibitor in the treatment of moderate to severe atopic dermatitis over an extended 140-week period.